NO20022441D0 - Fremgangsmåter for å behandle lupus basert på antistoff affinitet og screeningsmetoder, og preparater for anvendelse avdisse - Google Patents

Fremgangsmåter for å behandle lupus basert på antistoff affinitet og screeningsmetoder, og preparater for anvendelse avdisse

Info

Publication number
NO20022441D0
NO20022441D0 NO20022441A NO20022441A NO20022441D0 NO 20022441 D0 NO20022441 D0 NO 20022441D0 NO 20022441 A NO20022441 A NO 20022441A NO 20022441 A NO20022441 A NO 20022441A NO 20022441 D0 NO20022441 D0 NO 20022441D0
Authority
NO
Norway
Prior art keywords
methods
preparations
antibody affinity
treating lupus
screening methods
Prior art date
Application number
NO20022441A
Other languages
English (en)
Other versions
NO20022441L (no
Inventor
Matthew D Linnik
Patricia A Mcneely
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Pharma filed Critical Jolla Pharma
Publication of NO20022441D0 publication Critical patent/NO20022441D0/no
Publication of NO20022441L publication Critical patent/NO20022441L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20022441A 1999-11-28 2002-05-23 Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse NO20022441L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16771699P 1999-11-28 1999-11-28
PCT/US2000/042307 WO2001041813A2 (en) 1999-11-28 2000-11-28 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof

Publications (2)

Publication Number Publication Date
NO20022441D0 true NO20022441D0 (no) 2002-05-23
NO20022441L NO20022441L (no) 2002-07-09

Family

ID=22608518

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022441A NO20022441L (no) 1999-11-28 2002-05-23 Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse

Country Status (11)

Country Link
US (2) US7081242B1 (no)
EP (1) EP1233791A2 (no)
JP (1) JP2003516526A (no)
KR (1) KR20020059808A (no)
CN (2) CN1399562A (no)
AU (1) AU783282C (no)
CA (1) CA2391944A1 (no)
HK (1) HK1045944A1 (no)
MX (1) MXPA02005236A (no)
NO (1) NO20022441L (no)
WO (1) WO2001041813A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
JP2003516526A (ja) 1999-11-28 2003-05-13 ラ ホヤ ファーマシューティカル カンパニー 抗体親和性に基づいて狼瘡を処置する方法およびスクリーニング方法ならびにその使用のための組成物
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2004060320A2 (en) * 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
US20060229270A1 (en) * 2005-03-10 2006-10-12 La Jolla Pharmaceutical Company Methods of treating proteinuria by reducing double-stranded DNA antibodies
WO2009052415A1 (en) * 2007-10-17 2009-04-23 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus
CN102477079A (zh) * 2010-11-24 2012-05-30 中国人民解放军军事医学科学院基础医学研究所 一种新型多肽在系统性红斑狼疮诊断中的应用
WO2012116210A2 (en) * 2011-02-23 2012-08-30 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5391785A (en) 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
AU8869291A (en) 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
CA2073846C (en) 1991-07-15 2007-09-18 David S. Jones Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
ATE359830T1 (de) * 1993-09-08 2007-05-15 Jolla Pharma Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten
DK0743856T3 (da) 1994-02-28 2003-11-10 Univ Virginia Antigenbaserede heteropolymerer til behandling af autoimmune sygdomme
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
WO1997046251A1 (en) 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
EP0974550B1 (en) 1997-04-11 2004-08-11 Chiyoda Corporation Catalyst for preparation of synthesis gas and process for preparing carbon monoxide
US7794946B1 (en) 1998-02-04 2010-09-14 Life Technologies Corporation Microarray and uses therefor
AU2903899A (en) 1998-03-12 1999-09-27 Shearwater Polymers Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL141936A0 (en) 1998-09-10 2002-03-10 Univ Virginia Antibodies to c3b(1) for delivery of diagnostic and therapeutic agents to cancer cells
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US20010010818A1 (en) 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
JP2002531531A (ja) 1998-12-09 2002-09-24 ラ ホヤ ファーマシューティカル カンパニー 循環している抗体を減少させるための方法および処方物
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
JP2003516526A (ja) 1999-11-28 2003-05-13 ラ ホヤ ファーマシューティカル カンパニー 抗体親和性に基づいて狼瘡を処置する方法およびスクリーニング方法ならびにその使用のための組成物
AU2593901A (en) 1999-12-23 2001-07-03 Elusys Therapeutics, Inc. Therapeutic use of particles displaying pathogen-specific binding moieties
WO2001080883A1 (en) 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
JP2003535208A (ja) 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
WO2002046208A2 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
WO2002092011A2 (en) 2001-05-17 2002-11-21 La Jolla Pharmaceutical Company Methods of treating antibody-mediated pathologies using agents which inhibit cd21
US20030114405A1 (en) 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2004060320A2 (en) 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals

Also Published As

Publication number Publication date
JP2003516526A (ja) 2003-05-13
AU3970201A (en) 2001-06-18
HK1045944A1 (zh) 2002-12-20
WO2001041813A3 (en) 2002-01-03
EP1233791A2 (en) 2002-08-28
US7081242B1 (en) 2006-07-25
KR20020059808A (ko) 2002-07-13
CA2391944A1 (en) 2001-06-14
US20060142229A1 (en) 2006-06-29
WO2001041813A2 (en) 2001-06-14
NO20022441L (no) 2002-07-09
AU783282B2 (en) 2005-10-06
CN1399562A (zh) 2003-02-26
CN101422614A (zh) 2009-05-06
AU783282C (en) 2006-04-06
MXPA02005236A (es) 2004-03-19

Similar Documents

Publication Publication Date Title
DK0894135T3 (da) Multivalent og multispecifikt antigenbindingsprotein
NO975311D0 (no) Anordning og fremgangsmåte for å utföre brönnhullsfunksjoner
DE69735464D1 (de) Authentifizierungsverfahren, Kommunikationsverfahren und Informationsverarbeitungseinrichtung
EP0984727A4 (en) METHOD AND DEVICE FOR RECOVERY VESSEL IN MYOCARD
HK1028662A1 (en) Optically-based methods and apparatus for performing document authentication.
AU2508499A (en) Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
ZA986072B (en) Adsorption apparatus and methods.
ZA200309560B (en) Templated molecules and methods for using such molecules.
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
NO964306D0 (no) Ligninblanding, fremstilling og anvendelse derav
EP1529059A4 (en) LEPTIN PROTEIN, ANTI-ACID AND ANTIBODY FROM PIG
IL152725A0 (en) Human receptor proteins, related reagents and methods
NO984389D0 (no) Baggasje-skyveanordning, system og fremgangsmÕte for bruk
NO20022441D0 (no) Fremgangsmåter for å behandle lupus basert på antistoff affinitet og screeningsmetoder, og preparater for anvendelse avdisse
ATE420894T1 (de) Cytokine aus säugetieren, verwandte reagenzien und verfahren
DK0812440T3 (da) Fremgangsmåde til at behandle og opnå adgang til informationsobjekter, især dokumenter, samt system til udøvelse af fremgan
NL1007054A1 (nl) Foutcorrectiemethode en -inrichting.
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
NO971448D0 (no) Anti-Fas rekombinante antistoffer og DNA derfor
NO20011925L (no) Multippel domene glykoproteinhormoner og fremgangsmåter for anvendelse derav
EP1330535A4 (en) KINI-3 MOTOR PROTEIN AND METHODS OF USE THEREOF
GB9929431D0 (en) Polymer-coated surfaces for adsorbing macromolecules and their analytical methods
NO20021087L (no) Hengslet deksel til bruk i veier o.l.
ATA170496A (de) Schweissgerät und schweissverfahren, insbesondere widerstandsschweissverfahren
GB0006533D0 (en) Assays,methods and means

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application